Reparixin is primarily used in medical research and clinical settings for its anti-inflammatory properties. It functions as an inhibitor of CXCR1 and CXCR2 chemokine receptors, which play a significant role in neutrophil activation and migration. This makes it a potential therapeutic agent in conditions where inflammation and immune response need to be controlled, such as in acute respiratory distress syndrome (ARDS), sepsis, and ischemia-reperfusion injury. Additionally, it has been investigated for its role in reducing complications in organ transplantation by minimizing inflammatory damage. Reparixin is also being explored in cancer research to inhibit tumor-associated inflammation and metastasis. Its ability to modulate immune responses highlights its broad applicability in various inflammatory and immune-related disorders.